|
1
|
Immunohistochemical evaluation of autotaxin and lubricin in mild osteoarthritic rat model performing moderate physical activity. Acta Histochem 2022; 124:151936. [DOI: 10.1016/j.acthis.2022.151936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 07/25/2022] [Accepted: 07/27/2022] [Indexed: 11/20/2022]
|
|
2
|
Deng X, Salgado-Polo F, Shao T, Xiao Z, Van R, Chen J, Rong J, Haider A, Shao Y, Josephson L, Perrakis A, Liang SH. Imaging Autotaxin In Vivo with 18F-Labeled Positron Emission Tomography Ligands. J Med Chem 2021; 64:15053-15068. [PMID: 34662125 DOI: 10.1021/acs.jmedchem.1c00913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Autotaxin (ATX) is a secreted phosphodiesterase that has been implicated in a remarkably wide array of pathologies, especially in fibrosis and cancer. While ATX inhibitors have entered the clinical arena, a validated probe for positron emission tomography (PET) is currently lacking. With the aim to develop a suitable ATX-targeted PET radioligand, we have synthesized a focused library of fluorinated imidazo[1,2-a]pyridine derivatives, determined their inhibition constants, and confirmed their binding mode by crystallographic analysis. Based on their promising in vitro properties, compounds 9c, 9f, 9h, and 9j were radiofluorinated. Also, a deuterated analog of [18F]9j, designated as [18F]ATX-1905 ([18F]20), was designed and proved to be highly stable against in vivo radiodefluorination compared with [18F]9c, [18F]9f, [18F]9h, and [18F]9j. These results along with in vitro and in vivo studies toward ATX in a mouse model of LPS-induced liver injury suggest that [18F]ATX-1905 is a suitable PET probe for the non-invasive quantification of ATX.
Collapse
Affiliation(s)
- Xiaoyun Deng
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
- Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Fernando Salgado-Polo
- Oncode Institute and Division of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Tuo Shao
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Zhiwei Xiao
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Richard Van
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Jiahui Chen
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Jian Rong
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Achi Haider
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Yihan Shao
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Lee Josephson
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Anastassis Perrakis
- Oncode Institute and Division of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - Steven H Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| |
Collapse
|
|
3
|
Castagna D, Budd DC, Macdonald SJF, Jamieson C, Watson AJB. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. J Med Chem 2016; 59:5604-21. [DOI: 10.1021/acs.jmedchem.5b01599] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Diana Castagna
- WestCHEM, Department of Pure and Applied
Chemistry, University of Strathclyde, Glasgow, G1 1XL, U.K
| | - David C. Budd
- Medicines Research Centre, GlaxoSmithKline, Gunnel
Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K
| | - Simon J. F. Macdonald
- Medicines Research Centre, GlaxoSmithKline, Gunnel
Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K
| | - Craig Jamieson
- WestCHEM, Department of Pure and Applied
Chemistry, University of Strathclyde, Glasgow, G1 1XL, U.K
| | - Allan J. B. Watson
- WestCHEM, Department of Pure and Applied
Chemistry, University of Strathclyde, Glasgow, G1 1XL, U.K
| |
Collapse
|
|
4
|
Castagna D, Duffy EL, Semaan D, Young LC, Pritchard JM, Macdonald SJF, Budd DC, Jamieson C, Watson AJB. Identification of a novel class of autotaxin inhibitors through cross-screening. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00081e] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Starting from the known LPA1antagonist4, three novel series of autotaxin inhibitors exemplified by7,8and9were identified using a combination of scaffold hopping and ligand-based design.
Collapse
Affiliation(s)
- Diana Castagna
- WestCHEM
- Department of Pure and Applied Chemistry
- University of Strathclyde
- Glasgow
- UK
| | - Emma L. Duffy
- WestCHEM
- Department of Pure and Applied Chemistry
- University of Strathclyde
- Glasgow
- UK
| | - Dima Semaan
- Strathclyde Institute of Pharmacy and Biomolecular Science
- University of Strathclyde
- Glasgow
- UK
| | - Louise C. Young
- Strathclyde Institute of Pharmacy and Biomolecular Science
- University of Strathclyde
- Glasgow
- UK
| | | | | | - David C. Budd
- Fibrosis DPU
- GlaxoSmithKline
- Medicines Research Centre
- Stevenage
- UK
| | - Craig Jamieson
- WestCHEM
- Department of Pure and Applied Chemistry
- University of Strathclyde
- Glasgow
- UK
| | - Allan J. B. Watson
- WestCHEM
- Department of Pure and Applied Chemistry
- University of Strathclyde
- Glasgow
- UK
| |
Collapse
|